BidaskClub Downgrades TESARO, Inc. (TSRO) to Strong Sell

BidaskClub cut shares of TESARO, Inc. (NASDAQ:TSRO) from a sell rating to a strong sell rating in a research note released on Wednesday morning.

Several other research analysts also recently issued reports on TSRO. Zacks Investment Research downgraded shares of TESARO from a hold rating to a sell rating in a report on Wednesday, March 22nd. Argus initiated coverage on shares of TESARO in a research report on Friday, March 24th. They issued a buy rating and a $210.00 price target on the stock. Jefferies Group LLC boosted their price target on shares of TESARO from $80.00 to $124.00 and gave the company a hold rating in a research report on Monday, March 27th. Vetr upgraded shares of TESARO from a buy rating to a strong-buy rating and set a $178.33 price target on the stock in a research report on Monday, March 27th. Finally, Cowen and Company reiterated a market perform rating and set a $145.00 target price on shares of TESARO in a research report on Tuesday, March 28th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of Buy and an average target price of $173.74.

Shares of TESARO (NASDAQ TSRO) traded up 4.43% during midday trading on Wednesday, hitting $129.51. The stock had a trading volume of 749,038 shares. The firm has a 50 day moving average of $139.60 and a 200-day moving average of $151.77. The company’s market cap is $6.98 billion. TESARO has a one year low of $83.26 and a one year high of $192.94.

TESARO (NASDAQ:TSRO) last posted its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($2.55) EPS for the quarter, missing the Zacks’ consensus estimate of ($2.26) by $0.29. The company had revenue of $3.10 million for the quarter, compared to analyst estimates of $3.84 million. TESARO had a negative net margin of 910.35% and a negative return on equity of 96.49%. TESARO’s revenue was up 909.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($2.22) EPS. On average, analysts forecast that TESARO will post ($8.66) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by BBNS and is the property of of BBNS. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be read at https://baseballnewssource.com/markets/bidaskclub-downgrades-tesaro-inc-tsro-to-strong-sell/1237119.html.

In related news, VP Edward C. English sold 8,500 shares of TESARO stock in a transaction that occurred on Tuesday, June 6th. The shares were sold at an average price of $138.65, for a total transaction of $1,178,525.00. Following the sale, the vice president now directly owns 5,396 shares in the company, valued at approximately $748,155.40. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 40.50% of the stock is owned by company insiders.

A number of large investors have recently bought and sold shares of the company. Macquarie Group Ltd. increased its stake in TESARO by 4.8% in the fourth quarter. Macquarie Group Ltd. now owns 301,510 shares of the biopharmaceutical company’s stock valued at $40,547,000 after buying an additional 13,830 shares in the last quarter. Shell Asset Management Co. increased its position in shares of TESARO by 32.5% in the first quarter. Shell Asset Management Co. now owns 7,807 shares of the biopharmaceutical company’s stock worth $1,201,000 after buying an additional 1,913 shares during the period. Bellevue Group AG purchased a new position in shares of TESARO during the first quarter worth about $2,462,000. First Citizens Bank & Trust Co. purchased a new position in shares of TESARO during the first quarter worth about $288,000. Finally, First Trust Advisors LP purchased a new position in shares of TESARO during the first quarter worth about $3,993,000.

TESARO Company Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Analyst Recommendations for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Veteran Pitcher Bartolo Colon Considering Retirement
Veteran Pitcher Bartolo Colon Considering Retirement
Todd Frazier Traded to Yankees for Blake Rutherford and Others
Todd Frazier Traded to Yankees for Blake Rutherford and Others
Tigers Would Include Cash in Verlander Deal and Other MLB Trade Rumors
Tigers Would Include Cash in Verlander Deal and Other MLB Trade Rumors
Todd Frazier Trade to Boston Appears to Be Decided
Todd Frazier Trade to Boston Appears to Be Decided
Chicago White Sox Continue Rebuild Without Jose Quintana
Chicago White Sox Continue Rebuild Without Jose Quintana
Mike Trout Returns from Injury With Single and Stole Base
Mike Trout Returns from Injury With Single and Stole Base


Leave a Reply

 
© 2006-2017 BBNS.